360 related articles for article (PubMed ID: 31013941)
1. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options.
Iurlo A; Cattaneo D; Gianelli U
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013941
[TBL] [Abstract][Full Text] [Related]
2. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms.
Khan M; Siddiqi R; Gangat N
Leuk Res; 2017 Dec; 63():78-84. PubMed ID: 29121538
[TBL] [Abstract][Full Text] [Related]
4. Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.
Tallarico M; Odenike O
Curr Hematol Malig Rep; 2015 Jun; 10(2):112-7. PubMed ID: 25893311
[TBL] [Abstract][Full Text] [Related]
5. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S124-9. PubMed ID: 27521308
[TBL] [Abstract][Full Text] [Related]
6. Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm.
Rumi E; Harutyunyan A; Elena C; Pietra D; Klampfl T; Bagienski K; Berg T; Casetti I; Pascutto C; Passamonti F; Kralovics R; Cazzola M
Am J Hematol; 2011 Dec; 86(12):974-9. PubMed ID: 21953568
[TBL] [Abstract][Full Text] [Related]
7. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
Kundranda MN; Tibes R; Mesa RA
Curr Hematol Malig Rep; 2012 Mar; 7(1):78-86. PubMed ID: 22170483
[TBL] [Abstract][Full Text] [Related]
8. Leukemia secondary to myeloproliferative neoplasms.
Dunbar AJ; Rampal RK; Levine R
Blood; 2020 Jul; 136(1):61-70. PubMed ID: 32430500
[TBL] [Abstract][Full Text] [Related]
9. Accelerated and blast phase myeloproliferative neoplasms.
Saliba AN; Gangat N
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow findings in blast phase of polycythemia vera.
Hidalgo López JE; Carballo-Zarate A; Verstovsek S; Wang SA; Hu S; Li S; Xu J; Zuo W; Tang Z; Yin CC; Medeiros LJ; Bueso-Ramos CE; Tang G
Ann Hematol; 2018 Mar; 97(3):425-434. PubMed ID: 29285580
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm.
Rampal R; Mascarenhas J
Curr Opin Hematol; 2014 Mar; 21(2):65-71. PubMed ID: 24366192
[TBL] [Abstract][Full Text] [Related]
12. [Heterogeneity of leukemia cell phenotype. I. Variants of hetero- phenotype in relation to myeloid and erythrocytic markers of leukemic cells in acute leukemia and blast crisis of chronic myeloproliferative disorders].
Kemnitz J; Helmke M; Frend M; Bür T; Dominis M; Horitz H
Gematol Transfuziol; 1990 Aug; 35(8):9-14. PubMed ID: 2253865
[No Abstract] [Full Text] [Related]
13. [Heterogeneity of leukemic cell phenotype. II. Variants of hetero- phenotype in relation to myeloid and megakaryocytic markers of leukemia cells in acute leukemia and blast crisis of chronic myeloproliferative disorders].
Kemnitz J; Frend M; Dominis M
Gematol Transfuziol; 1990 Aug; 35(8):15-8. PubMed ID: 2253854
[No Abstract] [Full Text] [Related]
14. [Myeloproliferative neoplasms: histopathological and molecular pathological diagnosis].
Hussein K; Büsche G; Schlue J; Lehmann U; Kreipe H
Pathologe; 2012 Nov; 33(6):508-17. PubMed ID: 23085694
[TBL] [Abstract][Full Text] [Related]
15. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.
Tam CS; Nussenzveig RM; Popat U; Bueso-Ramos CE; Thomas DA; Cortes JA; Champlin RE; Ciurea SE; Manshouri T; Pierce SM; Kantarjian HM; Verstovsek S
Blood; 2008 Sep; 112(5):1628-37. PubMed ID: 18566326
[TBL] [Abstract][Full Text] [Related]
16. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia.
Lin P; Jones D; Medeiros LJ; Chen W; Vega-Vazquez F; Luthra R
Am J Clin Pathol; 2006 Oct; 126(4):530-3. PubMed ID: 16938665
[TBL] [Abstract][Full Text] [Related]
17. Relapse and cytogenetic evolution in myeloid neoplasms.
Ertz-Archambault N; Kelemen K
Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Gangat N; Guglielmelli P; Szuber N; Begna KH; Patnaik MM; Litzow MR; Al-Kali A; Foran JM; Palmer JM; Alkhateeb H; Elliott MA; Hanson CA; Pardanani A; Mannelli F; Vannucchi AM; Tefferi A
Am J Hematol; 2021 Jul; 96(7):781-789. PubMed ID: 33844862
[TBL] [Abstract][Full Text] [Related]
19. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
Greenberg PL
Clin Haematol; 1986 Nov; 15(4):973-93. PubMed ID: 3552351
[No Abstract] [Full Text] [Related]
20. Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.
Yogarajah M; Tefferi A
Mayo Clin Proc; 2017 Jul; 92(7):1118-1128. PubMed ID: 28688466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
